Drug profile · INN
naxitamab-gqgk
DANYELZA
naxitamab-gqgk (DANYELZA) is a disialoganglioside gd2 binding agent. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — naxitamab-gqgk
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
naxitamab-gqgk (DANYELZA) is a disialoganglioside gd2 binding agent. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Disialoganglioside GD2 binding agent
Primary target: Disialoganglioside GD2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is naxitamab-gqgk?
naxitamab-gqgk (DANYELZA) is a disialoganglioside gd2 binding agent. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for naxitamab-gqgk?
DANYELZA is a marketed brand name for naxitamab-gqgk. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of naxitamab-gqgk?
naxitamab-gqgk has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.